tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Dermatitis D003872 30 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Pharyngitis D010612 2 associated lipids
Shock D012769 11 associated lipids
Erythema D004890 22 associated lipids
Dermatomycoses D003881 17 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Cholelithiasis D002769 16 associated lipids
Fever D005334 35 associated lipids
Amenorrhea D000568 4 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hyperlipidemias D006949 73 associated lipids
Shock, Septic D012772 11 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Cough D003371 19 associated lipids
Paraproteinemias D010265 2 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Translocation, Genetic D014178 20 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Ovarian Cysts D010048 4 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Cardiomegaly D006332 31 associated lipids
Hypertension, Renal D006977 9 associated lipids
Metaplasia D008679 7 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Tachycardia D013610 7 associated lipids
Cicatrix D002921 9 associated lipids
Neutropenia D009503 15 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Urticaria D014581 13 associated lipids
Behcet Syndrome D001528 7 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Thrombophlebitis D013924 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
HIV Seropositivity D006679 15 associated lipids
Uveitis D014605 14 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Jordan ML et al. Tacrolimus for rescue of refractory renal allograft rejection. 1998 Transplant. Proc. pmid:9636511
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Neuhaus PJ Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. 1994 Transplant. Proc. pmid:7527961
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Wang XH et al. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation. 2000 Transplant. Proc. pmid:11119899
Jordan ML et al. FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. 1993 Transplant. Proc. pmid:7679827
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Jusko WJ and D'Ambrosio R Monitoring FK 506 concentrations in plasma and whole blood. 1991 Transplant. Proc. pmid:1721260
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Millis JM et al. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. 1996 Transplant. Proc. pmid:8623213
Yamamoto S et al. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. 2005 Jan-Feb Transplant. Proc. pmid:15808570
Aravot D et al. A new immunosuppressive protocol for lung transplantation: early promising results. 2003 Transplant. Proc. pmid:12644072
Molleví DG et al. Late xenograft rejection: comparison between liver and heart xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959212
Cai TH et al. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636572
Bond MMK et al. Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation? 2018 Transplant. Proc. pmid:29661443
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Lo CM et al. More effective immunosuppression with the use of FK506 after liver transplantation. 2000 Transplant. Proc. pmid:11120161
Moriuchi H et al. Mechanisms of immunosuppressive effects of FK 506 in light of apoptosis of hepatocytes and infiltrating lymphocytes in rat allografted livers. 2000 Transplant. Proc. pmid:11120182
Santos L et al. New-onset diabetes after transplantation: drug-related risk factors. 2012 Transplant. Proc. pmid:23146462
van Hooff JP et al. Dosing and management guidelines for tacrolimus in renal transplant patients. 1999 Transplant. Proc. pmid:10576046
McLachlan G et al. Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721291
Oliveira DB and Chang R Report of the first 118 tacrolimus-treated patients at St George's Hospital, London. 1999 Transplant. Proc. pmid:10576047
Asano T et al. Increased tacrolimus trough levels in association with severe diarrhea, a case report. 2004 Transplant. Proc. pmid:15518758
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Ichimaru N et al. Risk factors and incidence for lipid abnormalities in kidney transplant patients. 2015 Transplant. Proc. pmid:25891708
Merli M et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. 2010 Transplant. Proc. pmid:20534292
Goulet O et al. Small bowel transplantation alone or with the liver in children: changes by using FK506. 1998 Transplant. Proc. pmid:9636636
Gerber DA et al. Immunosuppressive agents: recent developments in molecular action and clinical application. 1998 Transplant. Proc. pmid:9636637
Fan Y et al. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. 2009 Transplant. Proc. pmid:19545736
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Masri M et al. Prograf five milligrams versus Tacrolimus medis in healthy volunteers: a bioequivalence study. 2013 Transplant. Proc. pmid:24314930
Xu M et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation. 1997 Transplant. Proc. pmid:9365631
Jacob DA et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. 2005 Transplant. Proc. pmid:15919432
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Ziolkowski J et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. 2003 Transplant. Proc. pmid:14529923
Junge G et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. 2005 Transplant. Proc. pmid:15919434
Takai K et al. Delayed graft function after renal transplantation from a non-heart-beating donors. 2003 Transplant. Proc. pmid:12591320
Yasunami Y et al. Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. 1992 Transplant. Proc. pmid:1376510
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Ciancio G et al. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. Transplant. Proc. pmid:27569936
Wilusz M et al. Effect of immunosuppressive therapy on the serum fatty acids of phospholipids fraction in patients after heart transplantation. 2014 Transplant. Proc. pmid:25380928
Motta I et al. FK 506 favors the generation of memory T cells in vitro. 1991 Transplant. Proc. pmid:1721324
Isai H et al. FK 506 and orthotopic liver transplantation in the rat. 1990 Transplant. Proc. pmid:1699329
Tannuri AC et al. Effects of immunosuppressants on hepatocyte cell mitosis during liver regeneration in growing animal models of partial hepatectomy. 2008 Transplant. Proc. pmid:18589165
Loh PT et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. 2008 Transplant. Proc. pmid:18589174
Mayer AD Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study. 2002 Transplant. Proc. pmid:12176452
Orlandi V et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. 2004 Transplant. Proc. pmid:15110639
Pohanka E et al. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. 2005 Transplant. Proc. pmid:15919490
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Shapiro R et al. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 1995 Transplant. Proc. pmid:7533432
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
Whiteside TL et al. Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721356
Fischereder M et al. Gynaecomastia following solid organ transplantation. 2002 Transplant. Proc. pmid:12270376
Budde K et al. Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 2002 Transplant. Proc. pmid:12176499
Iaria G et al. Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients. 2005 Jul-Aug Transplant. Proc. pmid:16182769
Kociszewska-Najman B et al. Congenital Infections in Neonates of Women With Liver or Kidney Transplants. 2016 Transplant. Proc. pmid:27496446
Shu KH et al. A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. 1998 Transplant. Proc. pmid:9838570
Bennett WM Renal complications after heart transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083019
Ko S et al. Predominant role of local immunosuppressive effect in enhanced efficacy of liposomal FK506 in organ transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123117
Rao AS et al. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. 1996 Transplant. Proc. pmid:8908140
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Thomson AW et al. Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. 1989 Transplant. Proc. pmid:2468203
Hossein-Nia M et al. Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721388
Baran DA et al. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. 2002 Transplant. Proc. pmid:12176547
Paul LC Overview of side effects of immunosuppressive therapy. 2001 Transplant. Proc. pmid:11377462
Rodrigo E et al. Histopathological findings according to Banff-97 classification system comparing tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176550
Jordán de Luna C et al. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. 2011 Jul-Aug Transplant. Proc. pmid:21839244
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 1999 Feb-Mar Transplant. Proc. pmid:10083507
Elinav H et al. Plasma oxidizability and plasma carbonyls, markers of oxidative stress, in liver transplant patients. 2001 Transplant. Proc. pmid:11543789
Opelz G Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. 1999 Feb-Mar Transplant. Proc. pmid:10083513
Batten P et al. Effect of cyclosporine A and FK 506 on human T cell responses to xenogeneic and allogeneic endothelium: relative resistance of T cell/porcine endothelial interactions. 1997 Feb-Mar Transplant. Proc. pmid:9123582
Troppmann C et al. FK 506 versus cyclosporine A for steroid-free synergistic combination therapy with rapamycin in a discordant large animal donor xenoislet transplant model. 1997 Feb-Mar Transplant. Proc. pmid:9123585
Braun N et al. Impairment of renal function following liver transplantation. 2003 Transplant. Proc. pmid:12826191
Cooper MH et al. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. 1991 Transplant. Proc. pmid:1721419
Yagura K et al. Pharmacokinetic characteristics of two types of liposomal FK 506. 1996 Transplant. Proc. pmid:8658708
Taber DJ et al. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. 2000 Transplant. Proc. pmid:10812156
Beckebaum S et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. 2004 Transplant. Proc. pmid:15621120
El-Sabrout R et al. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience. 2003 Transplant. Proc. pmid:12742474
Filler G et al. One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. 2002 Transplant. Proc. pmid:12176634
Rintala JM et al. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression. 2006 Transplant. Proc. pmid:17175234
Sahara H et al. Thymectomy does not abrogate long-term acceptance of MHC class I-disparate lung allografts in miniature Swine. 2006 Transplant. Proc. pmid:17175240
Ishikawa S et al. Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report. 2018 Transplant. Proc. pmid:29661455
Glanemann M et al. Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267194
Atillasoy E et al. Cholesterol levels long-term after liver transplant. 1998 Transplant. Proc. pmid:9723387
Quijano Y et al. Tolerance: a study in long-term surviving animals after small bowel transplantation. 1998 Transplant. Proc. pmid:9745494
Ybarra J et al. Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus. 2003 Transplant. Proc. pmid:14697943
Neff GW et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. 2003 Transplant. Proc. pmid:14697970
Yumiba T et al. Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. 1995 Transplant. Proc. pmid:7540780
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Velioglu A et al. Association of BK Virus Titers With Lymphocyte Count in Renal Transplant Patients. 2015 Transplant. Proc. pmid:26093733
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Ochiai T et al. Studies on FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450414
Immunosuppression: FK506. 1988 Transplant. Proc. pmid:2450415
Mehra MR et al. Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267442
Yura H et al. Development of a macromolecular prodrug of FK 506: II: In vitro study for FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636416
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Wu J et al. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. 1991 Transplant. Proc. pmid:1703683
Boggi U et al. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750373
Copley JB et al. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. 1998 Transplant. Proc. pmid:9636510